Checkpoint Therapeutics, Inc.
NASDAQ:CKPT
4.26 (USD) • At close May 30, 2025
Overzicht | Financiële gegevens
| Bedrijfsnaam | Checkpoint Therapeutics, Inc. |
| Symbool | CKPT |
| Munteenheid | USD |
| Prijs | 4.26 |
| Beurswaarde | 367,723,200 |
| Dividendpercentage | 0% |
| 52-weken bereik | 1.8 - 4.5 |
| Industrie | Biotechnology |
| Sector | Healthcare |
| CEO | Mr. James F. Oliviero III, C.F.A., CFA |
| Website | https://www.checkpointtx.com |
An error occurred while fetching data.
Over Checkpoint Therapeutics, Inc.
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)





